FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Not Applicable

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: irinotecan hydrochloride
Drug: capecitabine
Genetic: mutation analysis
Biological: bevacizumab
Biological: cetuximab
Genetic: gene expression analysis
Other: laboratory biomarker analysis
Other: immunohistochemistry staining method
Genetic: nucleic acid sequencing
Genetic: protein expression analysis
Genetic: polymerase chain reaction
Genetic: DNA analysis

First Posted Date: 2011-01-21

Last Posted Date: 2021-03-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT01280643

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Stage IA Esophageal Cancer
Stage IA Gastric Cancer
Stage IB Esophageal Cancer
Stage IIB Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage IIA Gastric Cancer
Stage IIIA Gastric Cancer

Interventions: Biological: bevacizumab
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2010-10-01

Last Posted Date: 2022-09-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 20

Registration Number: NCT01212822

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

Phase 1

Completed

Conditions: Cancer of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Cancer of the Stomach

Interventions: Drug: Vandetanib
Drug: 5 Fluorouracil (FU)
Drug: Carboplatin
Drug: Paclitaxel
Radiation: External Beam Radiation Therapy (RT)

First Posted Date: 2010-08-17

Last Posted Date: 2021-01-22

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 9

Registration Number: NCT01183559

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: ridaforolimus
Drug: vorinostat
Procedure: biopsy
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-07-26

Last Posted Date: 2021-02-21

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT01169532

Locations: 🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 2

Terminated

Conditions: GIST
Metastatic Disease

Interventions: Drug: Nilotinib with Imatinib
Drug: Nilotinib

First Posted Date: 2010-03-18

Last Posted Date: 2017-03-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 5

Registration Number: NCT01089595

Locations: 🇺🇸
Siteman Cancer Center, Washington University School of Mediciine, St Louis, Missouri, United States
🇺🇸
Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Locally Advanced Non-small Cell Lung Cancer

Interventions: Drug: vorinostat

First Posted Date: 2010-02-01

Last Posted Date: 2019-11-27

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 18

Registration Number: NCT01059552

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Phase 2

Completed

Conditions: Muscle Invasive Bladder Cancer
High Risk Urothelial Carcinoma of the Upper Urinary Tracts

Interventions: Drug: single arm dose dense MVAC

First Posted Date: 2009-12-14

Last Posted Date: 2019-09-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 54

Registration Number: NCT01031420

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Couple-Focused Intervention for Breast Cancer Patients

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Group Counseling

First Posted Date: 2009-07-15

Last Posted Date: 2016-02-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 611

Registration Number: NCT00940277

Locations: 🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸
Cooper Health System, Voorhees, New Jersey, United States
🇺🇸
Virtua Health System, Voorhees, New Jersey, United States

and more 2 locations

Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-09-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 37

Registration Number: NCT00900016

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Tailored Intervention for Melanoma Patient's Families

Not Applicable

Completed

Conditions: Melanoma

Interventions: Other: Reading materials and discussions
Other: Questionnaires

First Posted Date: 2009-01-01

Last Posted Date: 2014-05-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 553

Registration Number: NCT00816374

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy